Table 2 All-cause and NCD mortality trends in Latvia in 2020 compared to the average from 2015 to 2019: Joinpoint regression analysis
Years | # Joinpoints | Joinpoint week (95% CI) | WPCa (95% CI) | AWPCb (95% CI) |
|---|---|---|---|---|
All-cause mortality | ||||
Test for coincidence: p<0.001; Test for parallelism: p<0.001 | ||||
-0.22 (-0.64–0.19) | ||||
13 (7–16) | ||||
2015–2019 | -2.65* (-4.88– -0.37) | -0.15 (-0.42–0.13) | ||
3 | 18 (14–26) | |||
-0.46* (-0.79– -0.14) | ||||
34 (30–39) | ||||
0.90* (0.65– 1.15) | ||||
-0.32* (-0.48– -0.15) | ||||
2020 | 1 | 40 (36–43) | 0.62* (0.38–0.86) | |
3.72* (2.82–4.63) | ||||
Circulatory diseases (I10–I16; I20–I25; I60–I69) | ||||
Test for coincidence: p<0.001; Test for parallelism: p<0.001 | ||||
-0.31 (-1.14–0.53) | ||||
2015–2019 | 2 | 10 (5–17) | ||
-1.43* (-1.68–-1.17) | -0.17 (-0.38–0.03) | |||
32 (29–34) | ||||
1.28* (1.00–1.57) | ||||
-0.50* (-0.72–0.27) | ||||
2020 | 1 | 40 (33–43) | 0.40* (0.06–0.74) | |
3.36* (2.04–4.69) | ||||
Malignant neoplasms (C00–C97) | ||||
Test for coincidence: p<0.05 | ||||
2015–2019 | -0.33* (-0.57–0.09) | |||
1 | 25 (16–39) | -0.03 (-0.19–0.12) | ||
0.23* (0.03–0.43) | ||||
2020 | 0 | 0.08 (-0.08–0.24) | 0.08 (-0.08–0.24) | |
Test for parallelism: p=0.55 | ||||
-0.28* (-0.51– -0.06) | ||||
2015–2019 and 2020 combined | 1 | 24 (15–35) | -0.02 (-0.16–0.12) | |
0.20* (0.03–0.37) | ||||
Diabetes (E10–E14) | ||||
Test for coincidence: p<0.001; Test for parallelism: p<0.001 | ||||
2015–2019 | 0 | -0.30* (-0.59– -0.01) | -0.30*(-0.59– -0.01) | |
2020 | 0 | 0.83* (0.34–1.32) | 0.83* (0.34–1.32) | |
Chronic lower respiratory diseases (J40–J47) | ||||
Test for coincidence: p=0.465; Test for parallelism: p=0.381 | ||||
-1.85* (-2.63– -1.06) | ||||
2015–2019 and 2020 combined | 1 | 29 (23–38) | -0.70* (-1.36– -0.03) | |
0.73 (-0.41– 1.88) | ||||